Chemistry and Biology of Heparin and Heparan Sulfate

Garg, Hari G.; Linhardt, Robert J.; Hales, Charles A.

In stock
Regular price 151.750 KD inc. VAT
License
Table of contents
  • Contentsxiii
  • Prefacevii
  • Contributorsix
  • Chapter 1. Structure and Active Domains of Heparin1
  • I .Introduction1
  • II. Heparin Components2
  • III. Molecular Conformation of Heparin Residues and Sequences9
  • IV. Heparin Domains Involved in Biological Interactions11
  • V. Molecular Conformation of Active Domains17
  • VI. Conclusions19
  • Chapter 2. Structure and Function of Cell Associated and Pericellular Heparan Sulfate Proteoglycans29
  • I. Introduction29
  • II. Heparan Sulfate Synthesis30
  • III. Molecular Structure of Heparan Sulfate and Binding Ligands30
  • IV. Types of Heparan Sulfate Proteoglycans33
  • V. Syndecans33
  • VI. Role of Syndecan in Development35
  • VII. Glypicans37
  • VIII. Roles of Glypican in Tissue Development39
  • IX. Betaglycan and CD4440
  • X. Pericellular Heparan Sulfate Proteoglycans41
  • XI. Role in Disease Pathogenesis43
  • XII. Summary45
  • Chapter 3. Methods for Structural Analysis of Heparin and Heparan Sulfate55
  • I. Introduction55
  • II. Structure of Heparin and Heparan Sulfate56
  • III. Separation-Based Analysis of Heparin and Heparan Sulfate57
  • IV. Mass Spectrometric Analysis of Heparin and Heparan Sulfate62
  • V. Nuclear Magnetic Resonance Analysis of Heparin and Heparan Sulfate67
  • VI. New Methodologies for Structural Analysis of Heparin and Heparan Sulfate70
  • VII. Summary and Conclusions71
  • Chapter 4. Synthetic Approach to Define Structure-Activity Relationship of Heparin and Heparan Sulfa79
  • I. Introduction79
  • II. Biosynthesis80
  • III. Structure of Heparin/Heparan Sulfate82
  • IV. Chemical Synthesis of Defined Heparin Oligosaccharides84
  • V. Summary and Outlook129
  • Chapter 5. Biochemical and Pharmacological Rationale for Synthetic Heparin Polysaccharides143
  • I. Introduction143
  • II. Biological Activities and Mechanisms of Action of Heparin144
  • III. Fractionation and Fragmentation of Heparin147
  • IV. Elucidation of the Minimum Heparin Sequence for Binding to AT152
  • V. Synthesis of the Pentasaccharide Representing the Critical Binding Site of Heparin to AT154
  • VI. Pre-Clinical Pharmacology of Fondaparinux155
  • VII. Clinical Trials of Fondaparinux159
  • VIII. Derivatives of Pentasaccharide160
  • IX. Summary163
  • Chapter 6.Seperation and Sequencing of Heparin and Heparan Sulphate Saccharides179
  • I. Introduction179
  • II. Seperation of Heparin and Heparan Sulphate Oligosaccharides181
  • III. Heparin and Heparan Sulphate Sequencing192
  • IV. Discussion198
  • Chapter 7. Biosynthesis of Heparin and Heparan Sulfate203
  • I. Introduction203
  • II. Biosynthetic Enzymes and Transporters of Uridine Diphosphate- Sugars and 3'-Phosphoadenosine 5'-205
  • III. Biosynthesis of Heparin and Heparan Sulfate Backbones208
  • IV. Modification of the Sugar Backbones of Heparin and Heparan Sulfate220
  • V. Conclusions226
  • Chapter 8. Remodeling of Heparan Sulfation by Extracellular Endosulfatases245
  • I. Introduction245
  • II. Identification of Sulf Enzymes246
  • III. Expression and Enzymatic Activity of Sulf Enzymes248
  • IV. Signaling Regulatory Functions of Extracellular Sulfatases249
  • V. Sulf Function in Tumor and Angiogenesis253
  • VI. Conclusions255
  • Chapter 9. Heparan Sulfate Degradation by Heparanases259
  • I. Heparanase Proteins259
  • II. Synthesis of Heparanase 1261
  • III. Heparanase 1 Catalytic Activity269
  • IV. Biological Functions of Heparanase 1275
  • Chapter 10. Lysosomal Degradation of Heparin and Heparan Sulfate285
  • I. Introduction285
  • II. Transport of Heparin and Heparan Sulfate to the Lysosome286
  • III. endo-Degradation of Heparin and Heparan Sulfate286
  • IV. exo-Degradation of Heparin and Heparan Sulfate291
  • V. Transport of Degradation Products out of the Lysosome298
  • VI. Diagnostic and Clinical Aspects of the Mucopolysaccharides299
  • VII. Summary and Future Challenges in the Field303
  • Chapter 11. Heparin Regulation of the Complement System313
  • I . Introduction313
  • II. Background and History314
  • III. Heparin Regulation of the Complement System318
  • IV.The Effects of Heparin on the Alternative Pathway330
  • V . Conclusions337
  • Chapter 12 . Surface-Based Studies of Heparin/Heparan Sulfate-Protein Interactions: Considerations f345
  • I . Introduction345
  • II . Attachment347
  • III . Methods of Attachment to Surfaces354
  • IV . Detection of Binding Partners356
  • Chapter 13. Heparin Activation of Serpins367
  • I . Introduction367
  • II . General Features of Heparin Binding Serpins368
  • III . Antithrombin373
  • IV . Heparin Cofactor II379
  • V . The Others382
  • VI . Conclusions388
  • Chapter 14. Role of Heparan Sulfate in Fibroblast Growth Factor Signaling399
  • I . Introduction and Perspective399
  • II . Fibroblast Growth Factors400
  • III . FGF receptors402
  • IV.Interactions of the FGFs and FGFRs with Heparin405
  • V. Structural Studies of FGF, FGFR and Heparin Complexes414
  • VI. Conclusions and Future Perspectives426
  • Chapter 15. Role of Anticoagulant Heparan Sulfate in Mammalian Reproduction435
  • I. Introduction.435
  • II. Anticoagulant Heparan Sulfate Proteogly435
  • III. Anticoagulant Heparan Sulfate Proteoglycans in the Reproductive Tract437
  • IV. Reproduction in Mice Deficient in Anticoagulant Heparan Sulfate Proteoglycans451
  • V. Perspectives.453
  • Chapter 16. Glycol-Splitting as a Device for Modulating Inhibition of Growth Factors and Heparanase461
  • I. Introduction.461
  • II. Glycol-Split Heparins462
  • III. Protein-Binding and Associated Biological Properties of Glycol-Split Heparins467
  • IV. Conformational Implications of Glycol- Splitting474
  • V. Conclusions476
  • Chapter 17. Antithrombin Activation and Designing Novel Heparin Mimics483
  • I. Introduction483
  • II. Antithrombin Inhibition of Procoagulant Proteinases486
  • III. Structure of Heparin and Heparin Pentasaccharide487
  • IV. Mechanism of Heparin Activation of Antithrombin488
  • V. The Heparin Binding Site in Antithrombin491
  • VI. The Heparin Binding Site in Factor xa and Thrombin493
  • VII. Thermodynamics and kinetics of Heparin Binding to Antithrombin494
  • VIII. Rationale for Designing Functrional Mimics of Heparin496
  • IX. Heparin Mimics497
  • X. Conclusions504
  • Chapter 18. Influence of Heparin Chemical Modifications on Its Antiproliferative Properties.513
  • I. Introduction513
  • II. Background and Significance of Chemical Modification of Heparin514
  • III. Mechanisms Contributing to Heparin Inhibition of Smooth Muscle Cell Growth515
  • IV. Importance of 3-0-Sulfo Group on the Internal Glucosamine Residue of Pentasaccharide for Antipro516
  • V. Minimal Heparin Oligosaccharide Size Necessary for Antiproliferative Activity517
  • VI. Effect of Chemical Modification of Heparin on Its Antiproliferative Activity519
  • VII. Effect of the Type of Serum on Antiproliferative Activity524
  • VIII. Conclusions528
  • Chapter 19. Mechanisms of Cell Growth Regulation by Heparin and Heparan Sulfate533
  • I. Introduction.533
  • II. Modulation of Growth Factor Action534
  • III. Direct Regulation of Cell Growth544
  • IV. Growth Control in Disease546
  • V. Conclusions553
  • Chapter 20. Heparin and Low Molecular Weight Heparin in Thrombosis and Inflammation: Emerging Link571
  • I. Introduction571
  • II. Emerging Links Between Thrombosis and Inflammation: Potential Role of Heparin572
  • III. Heparin versus Low Molecular Weight Heparin575
  • IV. Heparin as an Anti-Inflammatory Molecule: Potential Mechanisms577
  • V. Conclusions578
  • Chapter 21. Basic and Clinical Differences of Heparin and Low Molecular Weight Heparin Treatment583
  • I. Introduction.583
  • II. Unfractionated Heparin and Newer Anticoagulant and Antithrombotic Drugs584
  • III. Low Molecular Weight Heparins and Their Impact on the Management of Thromnbotic and Vascular Di589
  • IV. Monitoring of Heparin and Low Molecular Weight Heparins.594
  • V. Clinical Trials with Low Molecular Weight Heparins597
  • VI. Generic Low Molecular Weight Heparins..598
  • VII. American College of Chest Physicians Consensus Recommendations600
  • VIII. Summary603
  • Chapter 22. Perlecan: An Extracellular Matrix Heparan Sulfate Proteoglycan that Regulates Key Events607
  • I. Introduction.607
  • II. Perlecan-The Gene, the Protein Core, and the Glycosaminoglycans607
  • III. Perlecan is a Key Extracellular Matrix Component in Basement Membranes and in the Development610
  • IV. Phenotypic Regulation of Vascular Cells by Perlecan611
  • V.Perlecan in Intimal Hyperplasia615
  • VI. Perlecan in Atherosclerosis618
  • VII. Perlecan and Angiogenesis621
  • VIII. Conclusions623
  • Chapter 23. Heparin and Low Molecular Weight Heparins in Clinical Cardiology637
  • I. Introduction637
  • II.Overview of Pharmacology637
  • III. Clinical Experience641
  • IV. Conclusions662
  • Chapter 24. Heparin-Induced Thrombocytopenia673
  • I. Introduction673
  • II. Pathogenesis673
  • III. Clinical Picture677
  • IV. Laboratory Testing for Heparin-Induced Thrombocytopenia Antibodies679
  • V. Treatment680
  • Chapter 25. Role of Heparan Sulfate in Cancer..699
  • I. Introduction.699
  • II. Structure Features of Glycosaminoglycans699
  • III. Biosynthesis and Degradation of Heparan Sulfate Glycosaminoglycans702
  • IV. Biological Functions of Heparan Sulfate Glycosaminoglycans703
  • V. Heparan Sulfate Glycosaminoglycans in Cancer706
  • Chapter 26. Use of Heparin Preparations in Older Patients727
  • I. Introduction..727
  • II. Aging and the Haemostatic System728
  • III. Unfractionated Heparin, Low Molecular Weight Heparins, and Fondaparinux: Pharmacological Proper729
  • IV. Unfractionated Heparin, Low Molecular Weight Heparins, and Fondaparinux: Clinical Use in Elderly731
  • V. Heparin and Low Molecular Weight Heparins: Risk of Bleeding in the Elderly734
  • VI. Conclusions and Perspectives737
  • Chapter 27. Advances in Low Molecular Weight Heparin Use in Pregnancy745
  • I. Introduction745
  • II. Pharmacology a Pharmacokinetics of Low Molecular Weight Heparin in Preganancy745
  • III. Indications for the Use of Low Molecular Weight Heparin in Pregnancy748
  • IV. Safety of Low Molecular Weight Heparin in Pregnancy759
  • V. Conclusions761
  • Subject Index769
Book details
  • Vendor Elsevier S & T
  • SKU 9780080448596
  • ISBN-13 9780080529059
  • Author Garg, Hari G.; Linhardt, Robert J.; Hales, Charles A.
  • Category Science
  • Subject Organic

Do you have questions about this book?

Ask an expert!

The chemistry, biochemistry and pharmacology of heparin and heparan sulfate have been and continue to be a major scientific undertaking - heparin and its derivative remain important drugs in clinical practice. Chemistry and Biology of Heparin and Heparan Sulfate provides readers with an insight into the chemistry, biology and clinical applications of heparin and heparan sulfate and examines their function in various physiological and pathological conditions. Providing a wealth of useful information, no other tome covers the diversity of topics in the field. Students, doctors, chemists, biochemists, and research scientists will find this book an invaluable source for updating their current knowledge of developments in this area.

* Comprehensively reviews all aspects of heparin and heparan sulfate research
* Uniquely describes the chemistry, biology and clinical application of heparins and heparan sulfates in one work
* Provides an invaluable source of knowledge of current developments for chemists, biochemists, medical doctors, researchers, students and practitioners